Page 1,045«..1020..1,0441,0451,0461,047..1,0501,060..»

Genomenon’s Mastermind Now Finds Therapies Associated with Genetic Drivers – Benzinga

Posted: April 28, 2020 at 6:47 pm

Mastermind Genomic Search Engine Identifies Approved and Off-Label Treatments Found Across the Medical Literature

ANN ARBOR, Mich. (PRWEB) April 28, 2020

Genomenon announced today that the latest release of the Mastermind Genomic Search Engine includes the ability to search by therapy. Mastermind users can now query the comprehensive database of genomic evidence for over 180,000 drugs, therapies, and other interventions.

This new offering furthers Genomenon's ability to catalogue a complete dataset of all "Genomic Associations" supported by medical evidence. These associations help clinical labs more accurately and rapidly diagnose patients, and pharmaceutical companies make ground-breaking discoveries in the effective treatment cancer and other genetic diseases. Mastermind was launched in 2017 with the ability to uncover associations between diseases, genes, and variants, and has since added ACMG/AMP classification, phenotypes, and now therapies. Each new component of association data increases the power of Mastermind to allow users to find genetic evidence, test or generate hypotheses, and draw clinical conclusions with confidence.

Searching by therapy provides significant value for oncologists making decisions on third-line therapies, where approved drugs or clinical trials are no longer effective for a cancer patient. Finding a comprehensive list of all therapies in the medical research tied to a cancer patient's genetic make-up is invaluable for treating these late-stage cancer patients.

The new search capability is also highly useful for clinicians making diagnostic and treatment decisions for patients with rare diseases. There are currently less than 800 FDA approved therapies for over 7,000 rare diseases, leaving many patients without an approved treatment option. In these cases, clinicians are required to scour the medical literature to find therapies associated with the patient's genetic profile; a time-consuming and often fruitless task.

About Genomenon

Genomenon is a genomic health IT company that connects patient DNA with the billions of dollars spent on research to help doctors diagnose and cure cancer patients and babies with rare diseases.

The Mastermind Genomic Search Engine is used by hundreds of genetic labs worldwide to accelerate diagnosis, increase diagnostic yield, and assure repeatability in reporting genetic testing results.

Mastermind Genomic Landscapes inform pharmaceutical and bio-pharma companies on precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence.

Genomenon was named 2020 Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan.

For more information, visit Genomenon.com.

For the original version on PRWeb visit: https://www.prweb.com/releases/genomenons_mastermind_now_finds_therapies_associated_with_genetic_drivers/prweb17078524.htm

Original post:
Genomenon's Mastermind Now Finds Therapies Associated with Genetic Drivers - Benzinga

Posted in Genetic medicine | Comments Off on Genomenon’s Mastermind Now Finds Therapies Associated with Genetic Drivers – Benzinga

What is antigen testing? How a new test could help track the coronavirus outbreak – NBCNews.com

Posted: April 28, 2020 at 6:47 pm

Cities and states across the United States are looking to expand coronavirus testing as part of efforts to emerge from lockdowns, but two major barriers remain: how to screen huge portions of the population, and how to do so quickly.

Antigen testing, which can offer faster results with less lab work, is the newest idea beginning to take hold.

"We have to have a breakthrough innovation in testing," Dr. Deborah Birx, the White House coronavirus task force coordinator, said in an interview Sunday on NBC News' "Meet the Press." "We have to be able to detect antigen rather than constantly trying to detect the actual live virus or the viral particles itself, and really move into antigen testing."

But antigen tests are not a single fix for the widespread testing shortages. There are currently no FDA-approved coronavirus antigen tests, and existing antigen tests for other viruses have their faults. But experts say these tools could become part of the broader solution.

Antigen tests are designed to detect viral proteins which, in the case of this coronavirus, would come from the spikes that coat the outside surface of the virus that trigger an immune response in the body.

At present, the main way to screen for COVID-19, the disease caused by the coronavirus, is through whats known as polymerase chain reaction (PCR) testing. These tests look for the coronavirus genetic material in a sample, but since the viral RNA is so tiny, it needs to be "amplified" or copied millions of times in a lab to get a result.

Let our news meet your inbox. The news and stories that matters, delivered weekday mornings.

"Theyre much more complicated to do, but PCR tests are the most sensitive," said Dr. Pedro Piedra, a professor of molecular virology and microbiology at the Baylor College of Medicine in Houston.

Though accurate, PCR testing is both resource and time intensive.

"Many of the current tests require multiple steps, manual pipetting of reaction components, and very accurate pipetting skills," Dr. Marie-Louise Landry, director of the Clinical Virology Laboratory at the Yale School of Medicine in New Haven, Connecticut, said in an email. "There are large instruments that can automate much of the PCR process and have a higher throughput, but these may still only do 300-400 samples in an eight-hour shift."

This makes it difficult to significantly ramp up PCR testing throughout the country.

"There will never be the ability on a [PCR] test to do 300 million tests a day or to test everybody before they go to work or to school, but there might be with the antigen test," Birx said April 17 during a coronavirus task force briefing.

Both antigen and PCR tests require nasal swabs, but antigen testing is simpler and could be done by primary care physicians. Patients would also receive results in less than an hour.

Antigen testing exists for the flu, in which doctors can administer "rapid influenza diagnostic tests" that deliver results within 15 to 30 minutes. Any breakthroughs in antigen testing for the coronavirus would hope to have similar outcomes.

"You dont need specialized personnel to run the test, its cost-effective and you get rapid results thats what youre looking for here," said Dr. Aron Lukacher, chair of the department of microbiology and immunology at Penn State College of Medicine in Hershey, Pennsylvania.

But antigen testing is not as sensitive as PCR testing, which means there is a greater chance that antigen tests could deliver false negative results. In other words, a patient could be infected but an antigen test is just not sensitive enough to detect it.

For some antigen tests, the rate of false negatives can be anywhere from 5 to 10 percent, according to Lukacher, which makes them less reliable. PCR testing, though not perfect, is thought to be more finely tuned because amplifying the virus genetic material also means that smaller amounts of the virus can be detected.

Antigen tests can also be challenging to develop because scientists need to be intimately familiar with the virus structure and biology in order to know what immune response will be triggered by these foreign substances.

"PCR tests have the advantage that you can test for many pathogens, not just one virus," Piedra said. "Antigen tests have to be built for specific viruses."

Health officials are hopeful that significant strides can be made in designing new diagnostic tools. Earlier this month, the federal governments Biomedical Advanced Research and Development Authority awarded more than $710,000 to a Pennsylvania-based company called OraSure Technologies to develop a rapid coronavirus test using saliva samples. Other researchers at E25Bio, a Massachusetts-based biotech company, are working on a coronavirus antigen test that could deliver results in 15 minutes.

Still, Lukacher said rapid antigen tests are unlikely to be a silver bullet for cities looking to restart their economies and emerge from lockdowns. Rather, any breakthroughs in antigen testing will likely have to be scaled up in tandem with PCR testing in order for health officials to determine how much the virus has spread in a community.

"The bottom line is we would want both rapid screening and the ability to test by PCR," Lukacher said. "All of these things have to be done in conjunction with one another."

Here is the original post:
What is antigen testing? How a new test could help track the coronavirus outbreak - NBCNews.com

Posted in Genetic medicine | Comments Off on What is antigen testing? How a new test could help track the coronavirus outbreak – NBCNews.com

How the pandemic made this virologist an unlikely cult figure – Science Magazine

Posted: April 28, 2020 at 6:47 pm

Christian Drosten admits the pandemic surprised him, despite having worked on coronaviruses for 17 years.

By Kai KupferschmidtApr. 28, 2020 , 12:25 PM

Sciences COVID-19 reporting is supported by the Pulitzer Center.

BERLINOn a recent Monday morning, Christian Drosten said goodbye to his wife and 2-year-old son in front of his apartment block and got on his bicycle for his daily commute to the Charit University Hospital here.

It looked like a scene from normal daily life. But of course it wasnt. His wife was going for a walk with their child instead of bringing him to the day care center, which was closed. The Berlin streets Drosten traversed were eerily quiet, most shops were closed, and some people on the sidewalks wore masks. Charits Institute of Virology, which Drosten heads, was studying exotic viruses, as always, but now one of those pathogens was killing patients in a hospital a few blocks away.

And instead of teaching virology to a few hundred students, Drosten now addresses hundreds of thousands of anxious Germans. Twicea week around 10 a.m., he sets a blue microphone on his desk, puts on headphones, and waits for a science journalist from German radio station NDR Info to call him. For the next 40 minutes, he answers questions about vaccines, respiratory droplets, school closures, or masks. The podcast, simply titled Coronavirus Update, has made Drosten the face, or rather the voice, of the pandemic in Germany. More than 1 million people regularly download what has become the countrys most popular podcast.

Drosten is one of the worlds foremost experts on coronaviruses; his career has closely tracked their emergence as a global threat. Now, he is also a popularif nerdyhero. In one widely shared meme, his face, with a pair of horn-rimmed glasses photoshopped on it, sits next to three movie stills of actor Jeff Goldblum, to whom he bears a passing resemblance. He has fought dinosaurs, body snatchers, and aliens, the caption reads, so Ill trust him with this virus too. Drostens cult status reminds Holger Wormer, a journalism professor at the Technical University of Dortmund, of Stephen Hawkings: Many people may not understand everything he says. But it is comforting to listen to someone explaining what is going on.

His calm, considered communication has earned Drosten widespread appreciation. Its a stroke of luck that we have someone here in Germany who is recognized worldwide as an expert on coronaviruses and who is willing and able to communicate so well, says Volker Stollorz, head of the German Science Media Center. Hes good at pointing out the limits of his own knowledge, Stollorz adds: Excellent researchers usually know very well where their expertise ends. On 20 April, the German Research Foundationannouncedit was awarding Drosten a one-off prize for outstanding science communication during the COVID-19 pandemic.

Christian Drostens career paralleled the emergence of coronaviruses as a serious human threat. He worked on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) and in January, his lab developed the first test for SARS-CoV-2, the new pandemic virus.

N. DESAI/SCIENCE

Drosten also explains coronaviruses to politicians. He has advised German Chancellor Angela Merkelthey chatted by phone for about an hour recently, he saysand Minister of Health Jens Spahn. He has been called Germanys coronavirus-explainer-in-chief and the coronavirus pope, the German equivalent of a coronavirus czar.

Yet colleagues describe Drosten, 47, as an unlikely character for his new role. He is not someone who seeks out this kind of attention, says Isabella Eckerle, a former lab member who now runs a laboratory for emerging viral diseases at the University of Geneva. Drosten says he wouldnt have stepped into the limelight if SARS-CoV-2 werent exactly the kind of virus he has spent most of his life studying. If this were influenza, for instance, I would not be doing this, he says.

Drostens coronavirus career effectively began on Saturday, 15 March 2003, when a 32-year-old doctor from Singapore named Leong Hoe Nam was taken off a plane in Frankfurt, Germany, and taken to the citys university clinic. Leong had treated patients in Singapore before attending an infectious diseases course in New York City, and had developed symptoms consistent with an alarming new respiratory disease that was rapidly spreading in Asia. That same day, the World Health Organization (WHO) had christened the new disease severe acute respiratory syndrome, or SARS.

At the time, Drosten was building up a lab for molecular diagnostics at the Bernhard Nocht Institute for Tropical Medicine in Hamburg, Germany. The Frankfurt virologists sent Leongs blood and other samples to Drosten, hoping he could help identify what was believed to be a new virus. But tests for everything from adenoviruses to paramyxoviruses came back negative.

About 1 week later, however, when Drosten was in Frankfurt to defend his Ph.D. thesis, the same virologists told him they had managed to grow the virus in a petri dish. Drosten realized this would allow him to use a new catch-all method he had developed for identifying unknown viruses, which amplified viral genetic material so it could be sequenced and checked against online databases. Drosten picked up a sample, then drove the 5 hours back to Hamburg in his old Opel and went straight to his lab. After a few days with little sleep, he had a small part of the new virus genome. The closest match was a cattle coronavirus that doesnt infect people. My first thought was, maybe it is some kind of contamination from the FCS, the fetal calf serum used to grow cells in the lab, Drosten recalls.

But he and his colleague Stephan Gnther quickly realized they were seeinga deadly new member of the family. At the time, medical students learned hardly anything about coronaviruses, Drosten says. The only two known to cause disease in humans, named OC43 and 229E, accounted for a small percentage of human colds every winter. This new virus was a very different beast. SARS killed 10% of the almost 8000 people it infected in nearly 30 countries before it was contained.

Researchers at the U.S. Centers for Disease Control and Prevention and at the University of Hong Kong realized the culprit was a coronavirus around the same time. But Drosten was the first to develop a diagnostic test, and he distributed the protocol freely on the internet. It earned him international recognition as well as the Federal Cross of Merit, an important German award. (Leong survived his bout with SARS and is now treating COVID-19 patients himself. He says he has not met Drosten, but reads every paper coming from his lab. Truly, he is an incredible scientist, with out-of-the-box thinking, Leong wrote in an email.)

Drosten grew up on a pig farm in northern Germany. He studied medicine in Frankfurt, the first person in his family to go to university, and rose quickly in German academia. After his stint in Hamburg, he became a full professor at the University of Bonn and, at 35, head of the Institute of Virology. His research interests were ideal preparation for COVID-19. He established a system for probing the function of the SARS virus genes and started to study viral evolution, looking for close relatives of human viruses in animals. Inone such study, his team discovered that mumps, which like measles is caused by a paramyxovirus, had jumped to humans from bats. They also showed that Nipah, another bat-borne virus, originated in Africa, even though it was discovered in Malaysia after hundreds of pig farmers there developed encephalitis in 1999.

Scientists discovered two new coronaviruses in the years after the SARS outbreak, both of which caused the common cold. Then in 2012, researchers isolated a new coronavirus that spelled greater danger. It came from a 60-year-old man in Saudi Arabia who had developed pneumonia. Intrigued, Drosten geared his research to the new agent, which was soon called Middle East respiratory syndrome (MERS) virus. In 2013, hereportedon a wealthy 73-year-old patient from Abu Dhabi, United Arab Emirates, who was treated for MERS in Germany and died. Relatives said the patient had cared for a sick racing camel before falling illthe first sign that camels might be involved.

Saudi Arabia, which had the most MERS cases and a multimillion-dollar camel racing industry, initially scoffed at the link. We dont think camels are involved, thenDeputy Minister of Health Ziad Memish said. But work from Drostens group and others soonconfirmed the suspicion. Memish and Drosten teamed up to study the new disease, and Drostens Bonn lab became a leading MERS hub. It developed a test to detect the virus RNA and then an antibody assay that helped show the virus had likely been infecting people in the region for decades.

The research yielded some unexpected insights. While looking for coronaviruses in camels, the scientistsfound pathogens closely related to 229E, one of the common cold coronaviruses, suggesting that virus, too, originated in camels. It was a warning sign, Drosten said at the time, that MERS could follow the same course as SARS, which had originated in bats, and evolve to become a true human disease. Animal coronaviruses, it seemed, posed a particular threat of sparking a pandemic.

Christian Drosten (center) at a March press conference with German Minister of Health Jens Spahn (right) and Petra Gastmeier, director of the Charit Institute of Hygiene and Environmental Medicine (left)

When another severe respiratory syndrome emerged this year, Drostenwho moved to the prestigious Charit University Hospital in 2017was prepared. After seeing the first rumors about a coronavirus in China online, Victor Corman, who leads the labs virus diagnostics group, began to search existing sequences of SARS-related coronaviruses, isolated from bats, for regions that were the same across different viruses. He was trying to guess what parts of a new SARS-like coronavirus might look like, in order to create a test. Based on those sequences, he designed and ordered 20 pairs of so-called primers, little snippets of DNA, that pair with a pathogens genome, so that it can be amplified and detected.

When Chinese researchers finally published the genome of the new virus from Wuhan on 10 January, Corman used the primers that best matched the viral sequence and prepared the diagnostic test almost immediately. WHO posted Cormans protocol on its website on 13 January, allowing countries around the world to produce a test themselves and detect imported cases of the new virus. Drosten predicted the test would also help scientists understand whether the virus was able to spread from human to human.

It was.

Three and a half months later, SARS-CoV-2, as it is now known, has traveled to all corners of the world, infecting millions of people and killing well over 200,000. It has forced countries from Austria to Zambia to shut down their economies and societies, causing immense suffering and igniting heated debates about the right way to deal with the threat.

Drosten concedes it has surprised him, despite his 17 years of work on coronaviruses and his knowledge of the threat they pose. I didnt think that SARS would come back like this, he saysas a virus that is both deadly and much more transmissible. It is adept at infecting cells of the upper respiratory tract, from which a cough can expel it, and unlike SARSbut like the fluit can spread before symptoms emerge. Thats pretty astonishing, Drosten says.

Drosten says a key reason for SARS-CoV-2s success may be a tiny part of the spike, the protein that sits on the virus surface and makes it look like a crown when seen through a microscope, giving coronaviruses their name. The spike protein attaches to a receptor on human cells called angiotensin-converting enzyme 2. Before the virus can enter the cell, however, a part of the protein has to be cleaved. The SARS-CoV-2 spike protein cleaves more readily than equivalent proteins in other coronaviruses, because it has evolved something called a polybasic cleavage site, which Drosten likens to the perforations on a notepad that make it easier to rip off a page. That feature may explain the virus rapid spread from cell to cell, he says.

Drosten started to warn of the new virus potential in TV interviews in January, but quickly grew exasperated. After long interviews, journalists often used one short quote that failed to convey the immense threat, he says. I actually called up some of them afterwards and told them: You are missing the boat on this. So when a producer from NDR asked Drosten in February whether he was willing to answer a few questions every day, his answer was swift: Traveling at the moment, like the idea, we can start Monday. (Drosten recently reduced the frequency to twice a week.)

Many people may not understand everything he says. But it is comforting to listen to someone explaining what is going on.

Theshows conversationis easygoing, and Drosten occasionally offers advice. In March, he told listeners to avoid beer from the tap, because glasses might not be cleaned thoroughly. When I go to a bar, I always order beer in a bottle, for many years now, he said. If Drosten is himself emotionally shaken by the pandemic and the way it is changing the world, he doesnt show it.

Drosten also seems unfazed by his newfound fame, but he gets annoyed when the focus drifts away from the science. He chided political journalists who asked whether important soccer matches and Germanys sacred Oktoberfest would need to be canceled, saying that was not his expertise. He bristles at stories describing his sensual lips and tousled hair. I talk about science, he says. I dont want to read about my haircut. Wormer says Drosten is doing a great job talking about the science, but is a tad nave about what interests the media. For some people going to the stadium is important and you just have to accept that, he says. For a public figure, a bit of mockery comes with the territory as well, he says.

Drosten has balked at suggestions that he has become a political player. He seemed genuinely angry after a spate of stories suggesting virologists had taken the reins of German government. If that doesnt change, we are reaching the point where science has to start an orderly retreat, he said on the podcast. His role as a political adviser is small, he told Science. Its not like Im in and out of ministries all day. When a German newspaper ran his photo under the headline Is this our new chancellor? he bristled at the idea.

Drosten receives hundreds of messages every day, most of them benign, he says. Old ladies somewhere telling me to remember to eat properly. That kind of thing. But he also gotdeath threats from people holding him responsible for the shutdown. The police are monitoring his inbox now, he says. It hasnt kept other virologists from starting their own coronavirus podcasts, including HIV researcher Hendrik Streeck, Drostens successor at the University of Bonn. A late-night show made fun of the phenomenon in a segment called Who let the docs out and German tabloidBildran a poll asking Which virologist do you trust the most? (Drosten won.)

Drosten feels most at home concentrating on his research. Virologist Marion Koopmans of Erasmus Medical Center in the Netherlands recalls seeing him during a technical planning meeting of a large research consortium, huddled at the back of the room with two or three others. Probably writing a Nature paper, she says. He doesnt like the blah blah blah.

But Drosten wants his research to save lives. Large cardboard boxes in his office hold supplies of two medicines waiting to be tried in the clinic. One is camostat mesylate, a pancreatitis drug approved in Japan that Drosten and others found can prevent both SARS-CoV and SARS-CoV-2 from entering cells. The other drug is niclosamide, used to treat tapeworms and other parasites. In a paper posted on the preprint server bioRxiv this month, Drostens colleague Marcel Mller showed that SARS-CoV-2 interferes with the cellular recycling process called autophagy. Its unclear how exactly that benefits the virus, but niclosamide counters the interference. Treatment with the compound reduced SARS-CoV-2s growth in cell culture by 70%, the authors write. Drosten hopes to start to enroll patients soon in a trial to test a combination of the two drugs.

For the moment, Drosten is learning what he can from sequencing virus samples and probing the pathogen in the biosafety level 3 lab in the institutes basement. He is also interested in how SARS-CoV-2 made its way from animals to humans. Hes fascinated by the role livestock appear to play as a bridge between bats, which are coronaviruses natural hosts, and humans. 229E and MERS came from camels, OC43 from cattle. SARS infected civets and also raccoon dogs, raised by the millions in Chinas fur industry. SARS-CoV-2s origin is unclear. But I dont believe that the answer will be three infected civet cats being sold in some fish market, Drosten says. There is going to be an industry involved in this somehow. He wonders whether raccoon dogs could be an intermediate host. I would love to take samples from 20 of these farms, he says.

Four months after the emergence of the pandemic, Germany is widely seen as a success story in Europe. The country tests widely for the virusthanks in part to that first assay, developed in Drostens laband has managed to keep case numbers low. Now, as in many countries, pressure is building to reopen shopping malls, bars, and restaurants. Drosten says this is partly because of a preliminary study by Streeck, whoannounced at a 9 April press conferencethat in one hard-hit German town, 15% of the population is already immune to COVID-19, suggesting the death rate is much lower than widely believed. The study has not been published, and Drosten says the data should not have been shared without any scientific scrutiny. He is worried some German states are moving too fast, which could lead to an explosive resurgence of the virus.

That concern has led him to depart from his science-only strategy. In this situation, for once, I have to express my opinion a little bit here in this podcast, he said on 22 April. Discussing press reports of shopping malls full of people, he said, Its sad to see that we may be in the process here in Germany of completely gambling away the advantage we have had.

With COVID-19 drugs and vaccines unavailable, such words may be the most powerful tool to curb the spread of the virus. And whether or not he likes it, Drostens podcast has given him real influence, says Marcel Fratzscher, head of DIW Berlin, an economic research institute. At this point, if Drosten says it is too early, that carries as much weight as Merkel saying it.

Follow this link:
How the pandemic made this virologist an unlikely cult figure - Science Magazine

Posted in Genetic medicine | Comments Off on How the pandemic made this virologist an unlikely cult figure – Science Magazine

Mother Of Three-Year-Old Abel Helson, Who Is Battling Acute Myeloid Leukemia (AML), Wants People To Send Him A Birthday Card – SurvivorNet

Posted: April 28, 2020 at 6:46 pm

Celebrating a birthday during quarantine might not be fun, but one mother in Kentucky is asking people to send her three-year old son, Abel Helson, birthday cards while he fights against a subtype of acute myeloid leukemia (AML) calledPure Erythroid Leukemia.

Concern over Helsons health started in October, when his family noticed his left eye was significantly drooping. At first it was brushed off by their family eye doctor, but the next month Helson started suffering from arm paralysis and difficulty moving his neck. In November, doctors performed a CT scan on Helson which showed he had three masses on his brain as well as one mass on both his neck and lower spine. He underwent surgery to remove the tumor on his neck.

Related:Writer Nora Ephron Quietly Fought Acute Myeloid Leukemia (AML)- The Exciting Advances In Treatment

After months of scans, Helson was ultimately diagnosed withPure Erythroid Leukemia, which is a subtype of AML.

Dr. Mikkael Sekeres breaks down what defines acute myeloid leukemia (AML)

Helsons birthday is on May 18, and since he will be spending it in the hospital, his mother shared an address with local news station WBKO where people can send Helson birthday cards to lift his spirits during treatment. People can send cards to:

Abel Helson206 E Third AveCentral City, KY 42330

In dozens of conversations with SurvivorNet, researchers have explained how patients are diagnosed with AML and what symptoms may be present.Dr. Gail Roboz, a medical oncologist at Weill Cornell Medicine, told SurvivorNet that AML symptoms may present themselves asshortness of breath, decreased exercise tolerance, unexplained bruising, or infections. In some cases, patients may have no symptoms of AML at all, and therefore are diagnosed unexpectedly during a routine health evaluation.

Related:Remembering LFO Lead Singer Rich Cronin Who Died From Acute Myeloid Leukemia (AML) The Incredible New Treatments Saving Lives

Once patients are given an AML diagnosis, Dr. Roboz says that its important to understand which subgroup of AML you fall into.Studying cytogenetics, which is a branch of genetics that looks at DNA structure, is key in acute myeloid leukemia (AML) research and treatment.Through cytogenetics, physicians will examine the types of chromosomes within patients in order to conclude into which subgroup of AML they fit, which is crucial in determining the best treatment they should receive. These prognostic subgroups include cytogenetic information, molecular genetic information, and mutations.

Dr. Gail Roboz explains how subgroups of AML are determined

This is something thats actually becoming very well known to patients because there are initiatives that are trying to have the patient be their own advocate and to say well, what is my subgroup of AML? What kind of AML do I have? Dr. Roboz says.

Learn more about SurvivorNet's rigorous medical review process.

Celebrating a birthday during quarantine might not be fun, but one mother in Kentucky is asking people to send her three-year old son, Abel Helson, birthday cards while he fights against a subtype of acute myeloid leukemia (AML) calledPure Erythroid Leukemia.

Concern over Helsons health started in October, when his family noticed his left eye was significantly drooping. At first it was brushed off by their family eye doctor, but the next month Helson started suffering from arm paralysis and difficulty moving his neck. In November, doctors performed a CT scan on Helson which showed he had three masses on his brain as well as one mass on both his neck and lower spine. He underwent surgery to remove the tumor on his neck.

After months of scans, Helson was ultimately diagnosed withPure Erythroid Leukemia, which is a subtype of AML.

Dr. Mikkael Sekeres breaks down what defines acute myeloid leukemia (AML)

Helsons birthday is on May 18, and since he will be spending it in the hospital, his mother shared an address with local news station WBKO where people can send Helson birthday cards to lift his spirits during treatment. People can send cards to:

Abel Helson206 E Third AveCentral City, KY 42330

In dozens of conversations with SurvivorNet, researchers have explained how patients are diagnosed with AML and what symptoms may be present.Dr. Gail Roboz, a medical oncologist at Weill Cornell Medicine, told SurvivorNet that AML symptoms may present themselves asshortness of breath, decreased exercise tolerance, unexplained bruising, or infections. In some cases, patients may have no symptoms of AML at all, and therefore are diagnosed unexpectedly during a routine health evaluation.

Related:Remembering LFO Lead Singer Rich Cronin Who Died From Acute Myeloid Leukemia (AML) The Incredible New Treatments Saving Lives

Once patients are given an AML diagnosis, Dr. Roboz says that its important to understand which subgroup of AML you fall into.Studying cytogenetics, which is a branch of genetics that looks at DNA structure, is key in acute myeloid leukemia (AML) research and treatment.Through cytogenetics, physicians will examine the types of chromosomes within patients in order to conclude into which subgroup of AML they fit, which is crucial in determining the best treatment they should receive. These prognostic subgroups include cytogenetic information, molecular genetic information, and mutations.

Dr. Gail Roboz explains how subgroups of AML are determined

This is something thats actually becoming very well known to patients because there are initiatives that are trying to have the patient be their own advocate and to say well, what is my subgroup of AML? What kind of AML do I have? Dr. Roboz says.

Learn more about SurvivorNet's rigorous medical review process.

Go here to read the rest:
Mother Of Three-Year-Old Abel Helson, Who Is Battling Acute Myeloid Leukemia (AML), Wants People To Send Him A Birthday Card - SurvivorNet

Posted in Genetic medicine | Comments Off on Mother Of Three-Year-Old Abel Helson, Who Is Battling Acute Myeloid Leukemia (AML), Wants People To Send Him A Birthday Card – SurvivorNet

Why this fundie is putting 60% of his portfolio in health stocks – Livewire Markets

Posted: April 28, 2020 at 6:46 pm

The search term adopt a healthcare worker has soared in popularity on Google in recent times as part of heartwarming campaigns to support frontline workers.

But one fundie from Pengana Capitalhas decided to take the interesting step of adopting a bunch of healthcare stocks developing innovative vaccines and treatments that could turn the tide against COVID-19 and other infectious diseases.

James McDonald, Portfolio Manager of the Pengana High Conviction Equities Fund, has been investing in the medical space for over 20 years. He revealed at a recent webinar that he used the downturn in March to bump up the funds healthcare exposure to a whopping 60%, from 40% previously.

McDonalds rationale for such a significant exposure is that while COVID-19 will bend and reshape industries and consumer behaviours in unpredictable ways, the need for healthcare will always remain and short-term headwinds such as deferring elective surgeries will inevitably pass.

He then dove into his top healthcare positions including 2 recently added, and how theyre tackling the worlds big problems. Two companies are ASX listed, while one is an American name making headlines.

ASX-listed Genetic Signatures is a new addition to the Pengana portfolio. The medical diagnostics producer recently developed a SARS-CoV-2 testing kit which has been approved by regulators here and in Europe, and is awaiting authorisation from the U.S.

While this means the company will benefit from a pickup in COVID-19 testing demand, its a smaller part of a bigger, more exciting story for GSS. McDonald says the installation of its testing products in hospitals and labs should help raise awareness of its other products that can detect gastroenteritis pathogens, numerous respiratory infections and antibiotic-resistant superbugs. These approved tests have a global opportunity of over $800 million against the backdrop of a broader medical diagnostics market growing at ~8% per annum. Plus, the company has a market value of $240 million with $40 million cash in the bank.

Nuclear medicine small-cap Telix Pharmaceuticals, whose Chief Medical Officer joined from Cochlear, is another company McDonald likes. Telixs market cap is $280 million and it holds $35 million of cash in the bank.

The company is developing a pipeline of molecularly-targeted radiation products to image and treat renal, prostate and brain cancer and has attracted the attention of oncology societies in Europe and the U.S. McDonald added that the Food and Drug Administration gave the company a glowing review about the efficacy of their prostate cancer imaging product (illumet) and Telix is hoping for final approvals by year-end.

Telixs prostate cancer imaging product has already been tested on 12,000 people at over 100 facilities and is currently being distributed by drug wholesaler Cardinal Health for US$300 per dose.

The other new addition is Gilead, a US$100 billion American healthcare giant and one of the frontrunners in developing a treatment for patients with COVID-19 with its Ebola drug remdesivir.

The effectiveness of the drug has been the subject of mixed press reports recently. On 16 April, a University of Chicago phase-3 trial showed rapid recoveries in patients with COVID-19, but about a week later leaked draft documents from the WHO suggested a trial in China highlighted that the drug had no benefit. But Gilead contends that trial was stopped early and proved inconclusive.

McDonald suggests investors turn their attention to trial results on patients with moderate symptoms due in late May, as a test on monkeys who were infected with COVID-19 had suggested that remdesivir could be effective where the disease is severe. Either way, he reckons any success around COVID-19 should only be seen as icing on the cake, as Gilead's powerhouse in HIV treatment keeps powering and it looks to find more innovations.

Other stocks

McDonald says hes not all in on healthcare and is positioning himself in other recovery names, such as Uber Technologies (NYS:UBER). He believes that the Ubers competitors will likely be hit much harder by the downturn but for the recovery, believes that consumers will prefer to move around in cars over public transport to keep social distancing. Hes also kept 20% of the portfolio in cash for other opportunities.

If you are interested in watching the full webinar, you can access it here

Stay up to date with my content by hitting the 'follow' button below and you'll be notified every time I post a wire. Not already a Livewire member? Sign up today to get free access to investment ideas and strategies from Australia's leading investors.

Follow this link:
Why this fundie is putting 60% of his portfolio in health stocks - Livewire Markets

Posted in Genetic medicine | Comments Off on Why this fundie is putting 60% of his portfolio in health stocks – Livewire Markets

April 28 morning update: The latest on the coronavirus and Maine – Bangor Daily News

Posted: April 28, 2020 at 6:44 pm

Linda Coan O'Kresik | BDN

Linda Coan O'Kresik | BDN

A teddy bear is seen in a window in a Hampden neighborhood.

Today is Tuesday. There have now been 1,023 confirmed cases of coronavirus infection in all of Maines counties, according to the Maine Center for Disease Control and Prevention.

Health officials on Monday confirmed the death of a man in his 70s from Kennebec County, bringing the statewide death toll to 51.

So far, 161 Mainers have been hospitalized at some point with COVID-19, the illness caused by the coronavirus, while another 549 people have fully recovered from the coronavirus, meaning there are 423 active cases in the state. Thats down from 433 on Sunday.

Heres the latest on the coronavirus and its impact in Maine.

The Maine CDC will provide an update on the coronavirus at 3 p.m. The BDN will livestream the briefing.

Democratic Gov. Janet Mills on Monday suggested at Mondays coronavirus briefing that she may loosen restrictions on businesses when her stay-at-home order expires on April 30. Mills told reporters she was likely to extend parts of a stay-at-home order. She signaled a shift by saying some restrictions might be lifted gradually based on whether workplaces can conduct business safely and not whether businesses are considered essential, saying she would announce a plan for extending the order on Tuesday.

Maine is now the last state in New England to not release data on coronavirus cases by city and town. Vermont started releasing ranges of cases Monday. The information does not specify which towns may have 5 or fewer cases. New Hampshire takes a similar tactic, but delineates towns that do not have any reported cases. Rhode Island reports the exact number of cases per municipality, as do Massachusetts and Connecticut. The Maine CDC has declined to release similar information, citing privacy concerns. It estimated it could take up to six months to compile that data in response to a Bangor Daily News Freedom of Access Act request last week.

Just four days after Maine confirmed its first case of the coronavirus, Seren Bruce received a different diagnosis that would nevertheless be shaped by the pandemic. On March 16, a doctor at Northern Light Cancer Care in Brewer who had reviewed Bruces bloodwork diagnosed her with non-Hodgkins lymphoma, a type of cancer that grows on the white blood cells. Bruces diagnosis has come at a particularly fraught time for cancer patients, who often have weakened immune systems as a result of their treatments or cancers, and who may be more likely to become seriously ill from the coronavirus. Now, hospitals have delayed all sorts of non-emergency services to preserve their resources and to prevent the virus from spreading among vulnerable patients, leading to delays in some care for cancer patients.

For more than a month now, visitors, including residents family members, have been barred from entering The Commons at Tall Pines in Belfast in hopes that the virus would not take root there. But the virus, stealthy and deadly, found its way in.

Calls placed to the Northern New England Poison Center from peoples homes have increased, according to Karen Simone, a toxicologist who runs the center at Maine Medical Center in Portland, but they do not appear to be a result of President Donald Trumps suggestion Thursday that ingesting certain household cleaners can keep people from getting the disease. Rather the increase seems to stem in part from more intense home cleaning efforts aimed at preventing the spread of the coronavirus and the occasional mishaps that result.

Bowdoin College in Brunswick is facing down a loss of more than $8 million from financial aid to assist low-income students with travel and other coronavirus-related costs and room-and-board refunds after the college opted to not have students return after spring break, making it one of the first Maine universities to close its campus in response to the coronavirus outbreak. Meanwhile, Bates College in Lewiston has already taken a financial hit of up to $2 million because of the coronavirus and the colleges president, Clayton Spencer, anticipates worse to come.

The Maine CDCs headquarters reopened Monday after a coronavirus exposure briefly shuttered the headquarters of the agency responsible for leading the state response to the pandemic.

The eagerly anticipated second round of federal stimulus loans aimed at helping small businesses pay employees during the coronavirus outbreak rolled out on Monday, when the system processing loans almost immediately came to a halt before it began working again sluggishly several hours later.

The billions of dollars in coronavirus relief targeted at small businesses may not prevent many of them from ending up in bankruptcy court. Business filings under Chapter 11 of the federal bankruptcy law rose sharply in March, and attorneys who work with struggling companies are seeing signs that more owners are contemplating the possibility of bankruptcy. Companies forced to close or curtail business due to government attempts to stop the virus spread have mounting debts and uncertain prospects for returning to normal operations. Even those owners receiving emergency loans and grants arent sure that help will be enough.

As of early Tuesday morning, the coronavirus has sickened 988,469 people in all 50 states, the District of Columbia, Puerto Rico, Guam, the Northern Mariana Islands and the U.S. Virgin Islands, as well as caused 56,253 deaths, according to Johns Hopkins University of Medicine.

Elsewhere in New England, there have been 3,003 coronavirus deaths in Massachusetts, 2,012 in Connecticut, 233 in Rhode Island, 60 in New Hampshire and 47 in Vermont.

Before her double-lung transplant, Joanne Mellady could barely put on a shirt without losing her breath. Afterward, she barely stopped moving. Mellady, who died of the coronavirus in March, had a bucket list that made her family blush. Mellady, a 67-year-old from New Hampshire, transformed herself from a shy person dependent on oxygen around the clock to a vivacious risk taker willing to try almost anything. Hang gliding, skiing, skateboarding and kayaking were among the thrills she took on.

Follow this link:
April 28 morning update: The latest on the coronavirus and Maine - Bangor Daily News

Posted in Maine Stem Cells | Comments Off on April 28 morning update: The latest on the coronavirus and Maine – Bangor Daily News

Bringing the immune system into balance may be the key to managing debilitating thyroiditis – St George News

Posted: April 27, 2020 at 2:52 pm

Stock image, St. George News

FEATURE When it comes to hypothyroid patients in the United States, approximately 80-90% of them have an autoimmune disease called Hashimotos thyroiditis.

With Hashimotos, an errant immune system attacks and chews up the thyroid gland to the point where it becomes inflamed, swollen, impaired and unable to produce the hormones it should to maintain health and quality of life. Sometimes during the typically long process of destruction that characterizes Hashimotos, the gland even dumps too much hormone for short periods of time, creating hyper/hypo cycles that can drive patients and their doctors to the end of their ropes.

Despite Hashimotos dominance in the thyroiditis category, doctors seldom diagnose it via lab tests because insurance companies are unwilling to pay for the tests. They know that conventional medical treatment for Hashimotos hormone replacement therapy is the same as the treatment for other forms of hypothyroidism.

The thinking goes like this: If the treatment is going to be the same no matter what, why pay for extra testing? Seems logical enough. But is it? Lets explore.

A large number of my patients are middle-aged women who come to my office after having been told by doctors that they are hypothyroid. They have been taking various hormone replacement medications to get their laboratory numbers especially their pituitary TSH and thyroid T4 levels back into normal ranges.

Despite the treatment, including jumps in dosage, these women continue to exhibit many different symptoms, including symptoms of hypothyroidism that hormone replacement was supposed to alleviate.

When that approach failed to relieve symptoms for these women, another diagnosis often followed, usually from the following sickness menu: depression, cyclothymia, PMS, chronic fatigue syndrome, fibromyalgia and anxiety disorder. For these women, the additional diagnoses have meant more drugs and more side effects from those drugs yet little, if any, relief from the misery they suffer. What is going on?

The immune system has two sides. One side attacks invaders while the other side creates antibodies that tag invaders for later attack and removal. With Hashimotos, one side has gone hyper, tricking the body into attacking its own cells. Further, when a confused immune system creates errant antibodies that attack the thyroid, those inflammatory antibodies also convince other body cells to resist thyroid hormones present in the bloodstream.

Thats not good.

Thyroid hormones are meant to trigger important metabolic functions within cells. When the cells resist, the hormones already present dont work well and energy levels tank. That is why a patient can have adequate levels of thyroid hormones in the bloodstream and still have symptoms of low thyroid.

The key to managing the immune system of a Hashimotos patient is to find out whether the patient indeed has Hashimotos. We then can find out what side of the immune system is out of kilter and bring it back into balance with the other. This doesnt mean suppression, which is dangerous; it means modulation.

Once the proper laboratory panels are run including a comprehensive thyroid panel and after looking for blood sugar disorders, other hormone imbalances, anemia patterns and adrenal gland dysfunction, the needed approach usually becomes quite clear.

But that approach must be tailored to each individual. One size does not fit all because too many things are often out of kilter at the same time with Hashimotos. Whats more, doctors need time to truly listen to patients, a service that is in short supply under todays insurance-driven health care system.

Treating Hashimotos, whether actively diagnosed or not, as a thyroid disease requiring only hormone replacement is fighting the wrong battle. Hashimotos thyroid is basically an immune system problem that just happens to be targeting the thyroid. Manage the immune system problem well and the thyroid gland will often recover stability.

Moreover, further damage and continued symptoms can usually be averted by finding out what triggered Hashimotos in the first place, managing the diet, evaluating GI function for issues, altering general lifestyle behavior and supplementing with immune-system modulating plant extracts commonly used in functional medicine.

Yes, hormone replacement may still be needed if too much damage has been done and the gland is no longer able to produce sufficient amounts. Although Hashimotos is the result of some form of genetic susceptibility to environmental and other triggers and cant be reversed in the current science, it can be managed and held at bay very well to regain quality of life.

Written byEast West Health Wellness Experts.

This article was first published in St. George Health and Wellness magazine.

Email: news@stgnews.com

Twitter: @STGnews

St. George Health and Wellness magazine joins with St. George News to provide feature articles focused on fitness, nutrition, health, mind and body, and family wellness. The St. George Health and Wellness magazine is distributed to hundreds of locations every other month throughout St. George and surrounding areas. Articles are written by local experts and providers - for more information on any of these, visit http://www.saintgeorgewellness.com.

See more here:
Bringing the immune system into balance may be the key to managing debilitating thyroiditis - St George News

Posted in Hormone Replacement Therapy | Comments Off on Bringing the immune system into balance may be the key to managing debilitating thyroiditis – St George News

Improved Survival with Adjuvant Chemoendocrine Therapy in HR+/ERBB2+ Tumors – Cancer Network

Posted: April 27, 2020 at 2:52 pm

In a research letter published inJAMA Network Open, researchers suggested that there is a correlation between improved survival and adjuvant chemoendocrine therapy, specifically for hormone receptor (HR)-positive, ERBB2 (formerly HER2/neu)-positive tumors 8 mm to 10 mm.

According to the researchers, recurrence rates for patients with HR-positive, ERBB2-positive tumors range from less than 5% up to 25% at 5 years, with or without adjuvant treatments. With randomized trial data on the role of chemotherapy for small tumors currently lacking in this disease space, the cutoff size at which chemotherapy should be omitted remains uncertain.

While relevant prospective clinical trials continue to accrue data, the researchers indicated that this data could help clinicians in decision-making regarding adjuvant systemic therapy for patients with small HR-positive, ERBB2-positive breast cancers.

It is evident that tumors 10 mm and smaller represent a heterogeneous group whose treatment should be tailored to improve the risk-to-benefit ratio of systemic therapy, the authors wrote. We acknowledge the inherent challenges of diagnostic concordance in the context of millimeter-based decisions, which underscores the importance of expert pathology review.

Using the US National Cancer Database, researchers queried for female patients with HR-positive, ERBB2-positive pT1a-bN0 breast cancer diagnosed between 2010 and 2015 who received hormone therapy with or without chemotherapy. The Kaplan-Meier method and Cox multivariable analysis were then performed to evaluate overall survival, and propensity score matching was based on the nearest neighbor method in a 1:1 ratio without a replacement.

Overall, 10,065 patients were identified for the study, including 5,346 patients who received chemotherapy and 4,719 patients who did not. On multivariable analysis, multiagent chemotherapy was correlated with an improved overall survival (hazard ratio [HR], 0.69; 95% CI, 0.52-0.90;P= 0.006), and tumor size as a continuous variable was associated with worse mortality (for every 1-mm increase, HR, 1.07; 95% CI, 1.03-1.12;P= 0.002). Moreover, there was a statistically significant interaction found between multiagent chemotherapy and tumor size (Pfor interaction = 0.02).

Cox multivariable analysis was repeated with each tumor size cutoff, ranging from 2 mm to 9 mm, and an 8-mm cutoff was suggested to be statistically significant (Pfor interaction = 0.01), with a large effect size and narrow 95% CI on subgroup analysis. Further, multiagent chemotherapy was not associated with improved overall survival for tumors smaller than 8 mm (HR, 1.00; 95% CI, 0.70-1.43;P= 0.99), compared with tumors 8 mm to 10 mm, which therefore favors the use of chemotherapy (HR, 0.53; 95% CI, 0.36-0.78;P= 0.001). Additionally, comparable findings were seen in 1,641 and 648 matched pairs, respectively (tumors <8 mm, HR, 0.88; 95% CI, 0.58-1.34;P= 0.55; tumors 8-10 mm, HR, 0.48; 95% CI, 0.27-0.85;P= 0.01).

Our study is limited by the lack of specific systemic therapy regimens, the authors wrote. Subgroup analysis using this cohort would be difficult because of the small sample sizes, as neither systemic therapy alone is a definitive recommendation by [the] National Comprehensive Cancer Network in this setting.

Because the National Cancer Database is a deidentified data set, ethical approval was waived by the Roswell Park Comprehensive Cancer Center institutional review board. Moreover, the study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

Reference:

Ma SJ, Oladeru OT, Singh AK. Association of Survival With Chemoendocrine Therapy in Women With Small, Hormone Receptor-Positive, ERBB2-Positive, Node-Negative Breast Cancer.JAMA Network Open. doi:10.1001/jamanetworkopen.2020.2507.

Read the original here:
Improved Survival with Adjuvant Chemoendocrine Therapy in HR+/ERBB2+ Tumors - Cancer Network

Posted in Hormone Replacement Therapy | Comments Off on Improved Survival with Adjuvant Chemoendocrine Therapy in HR+/ERBB2+ Tumors – Cancer Network

Hormone Replacement Therapy (HRT) Market 2020 COVID19 Impact Analysis on Key Players | Spice Technologies, FreshBooks, ActCAD and Others – Latest…

Posted: April 27, 2020 at 2:52 pm

Futuristic Reports, The growth and development of Global Hormone Replacement Therapy (HRT) Market Report 2020 by Players, Regions, Type and Application, forecast to 2026 provides industry analysis and forecast from 2020-2026. Global Hormone Replacement Therapy (HRT) Market analysis deliver important insights and provide a competitive and useful advantage to the pursuers. Hormone Replacement Therapy (HRT) processes, economic growth is analyzed as well. The data chart is also backed up by using statistical tools. Simultaneously, we classify different Hormone Replacement Therapy (HRT) market based on their definitions. Downstream consumers, and upstream materials scrutiny are also carried out. Each segment includes in-depth explanation of the factors that are useful to drive and restrain it.

Key Players mentioned in the study are Spice Technologies, FreshBooks, ActCAD, Bluebeam Software, Trimble, Graphisoft, Clearview Software, progeSOFT, Chief Architect, Vectorworks, Asynth, Computer Systems Odessa, Base Builders, Newforma, Tekla, eTeks, SoftPlan Systems, Floorplanner, RoomSketcher, Gather

For Better Understanding, Download FREE Sample Copy of Hormone Replacement Therapy (HRT) Market Report @ https://www.futuristicreports.com/request-sample/66100

Key Issues Addressed by Hormone Replacement Therapy (HRT) Market: It is very significant to have Hormone Replacement Therapy (HRT) segmentation analysis to figure out the essential factors of growth and development of the market in particular sector. The Hormone Replacement Therapy (HRT) report offers well summarized and reliable information about every segment of growth, development, production, demand, types, application of the specific product which will be useful for player to focus and highlight on.

Businesses Segmentation of Hormone Replacement Therapy (HRT) Market:

On the basis on the applications, this report focuses on the status and Hormone Replacement Therapy (HRT) outlook for major applications/end users, sales volume, and growth rate for each application, including-

Small and medium-sized enterprises Large enterprises

On the basis of types/products, this Hormone Replacement Therapy (HRT) report displays the revenue (Million USD), product price, market share and growth rate of each type, split into-

On-premises Cloud based Mobile Solutions

Grab Best Discount on Hormone Replacement Therapy (HRT) Market Research Report [Single User | Multi User | Corporate Users] @ https://www.futuristicreports.com/check-discount/66100

Hormone Replacement Therapy (HRT) Market Regional Analysis Includes:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) North America (the United States, Mexico, and Canada.) South America (Brazil etc.) The Middle East and Africa (GCC Countries and Egypt.)

Hormone Replacement Therapy (HRT) Insights that Study is going to provide:

Gain perceptive study of this current Hormone Replacement Therapy (HRT) sector and also possess a comprehension of the industry; Describe the Hormone Replacement Therapy (HRT) advancements, key issues, and methods to moderate the advancement threats; Competitors In this chapter, leading players are studied with respect to their company profile, product portfolio, capacity, price, cost, and revenue. A separate chapter on Hormone Replacement Therapy (HRT) market structure to gain insights on Leaders confrontational towards market [Merger and Acquisition / Recent Investment and Key Developments] Patent Analysis** Number of patents filed in recent years.

Table of Content:

Global Hormone Replacement Therapy (HRT) Market Size, Status and Forecast 20261. Market Introduction and Market Overview2. Industry Chain Analysis3. Hormone Replacement Therapy (HRT) Market, by Type4. Hormone Replacement Therapy (HRT) Market, by Application5. Production, Value ($) by Regions6. Production, Consumption, Export, Import by Regions (2016-2020)7. Market Status and SWOT Analysis by Regions (Sales Point)8. Competitive Landscape9. Analysis and Forecast by Type and Application10. Channel Analysis11. New Project Feasibility Analysis12. Market Forecast 2020-202613. Conclusion

Enquire More Before Buying @ https://www.futuristicreports.com/send-an-enquiry/66100

For More Information Kindly Contact:

Futuristic ReportsTel: +1-408-520-9037Email: [emailprotected]Media Release: https://www.futuristicreports.com/press-releases

Follow us on Blogger @ https://futuristicreports.blogspot.com/

Read more:
Hormone Replacement Therapy (HRT) Market 2020 COVID19 Impact Analysis on Key Players | Spice Technologies, FreshBooks, ActCAD and Others - Latest...

Posted in Hormone Replacement Therapy | Comments Off on Hormone Replacement Therapy (HRT) Market 2020 COVID19 Impact Analysis on Key Players | Spice Technologies, FreshBooks, ActCAD and Others – Latest…

School is out. Many young people are not – the impact of lockdown on LGBTQ youth – Gay Times Magazine

Posted: April 27, 2020 at 2:52 pm

Following the announcement of the UK lockdown in March, we have all had no choice but to quickly adapt to a different way of living in order to ensure the safety of ourselves and others.

Our daily routines have been completely altered, many of our plans postponed or cancelled, and we have been unable to meet relatives and friends who we may ordinarily have seen on a regular basis. It has been tough for everyone. Unfortunately, the situation is especially difficult for the younger members of our community who are in lockdown with unsupportive families.

Research by LGBTQ youth charity, Just Like Us, suggests that LGBTQ young people may struggle more at home than cis straight young people, as they are more likely to initially confide in friends rather than a family member; the reverse is true for their non LGBTQ peers.

For so many closeted young people including some Just Like Us volunteer ambassadors moving out of home for college, university or work is an opportunity to come out and build a support network. Meeting other LGBTQ young people and moving away from home has been a life-changing experience for many of us, who kept our identities hidden from our families for many years.

The closure of universities, colleges and workplaces means that many LGBTQ young people are now separated from their chosen friends and family, and are having to re-enter unsupportive households. My co-ambassador Nicole said, Having to go from being out and living on my own, then back to being closeted in a homophobic household, has hit hard.

Anna, another ambassador, whose family is Catholic, says, I came out to my family last year after I began my second year at uni and started dating a girl. I knew they wouldnt take it well initially, but thought they would at least be able to process what Id told them by the time I came home. Now Im back home [early] they barely speak to me and when they do, they criticise me for my sinful lifestyle Being back at home with my family has definitely taken its toll on my mental health.

Our trans ambassadors face additional problems. Joel says, Im really lucky to be isolating with people who are very trans friendly and affirming, but its medical stuff thats my concern. Its causing a lot of worries around my transition. Ive recently changed from getting my Hormone Replacement Therapy (HRT) injections to gel. Im due a blood test in two weeks, but my GP isnt doing any face to face appointments so I cant have one, and if I cant have my bloods okayed at safe levels on the new HRT, my endocrinologist will probably stop it until we can prove my liver is coping.

There are other trans folk who are in similar boats. My friend has missed one injection, as he has a condition meaning he cant self-inject, and the nurse wont make an appointment to inject him at this time. Others have had their gender affirming surgeries cancelled. Theres also the fact that Gender Identity Clinics are all closed right now, so the already ridiculous wait times (currently around 26 months from referral to first appointment and 20 months between appointments for the Newcastle clinic) are only going to be longer when all this is over.

At Just Like Us, we work with LGBTQ young people in schools, many of whom are not yet out to their friends and relatives. Now that schools are closed, these kids are with their families 24/7, and if they have not yet had the chance to build a support network, this could be incredibly isolating. Many will be suppressing their identities due to the fear of being rejected by their families, and with most currently entirely dependent on their families, akt (Albert Kennedy Trust), the LGBTQ youth homelessness charity, has advised LGBTQ young people not to come out to family during the lockdown, because of the consequences of a potential negative response. In addition, the possibility that university and college courses may commence online in September will come as a huge disappointment for those who are hoping to move away from unsupportive households.

But despite this, were coming together to support one another during these difficult times, and our LGBTQ young adults are finding great ways to support themselves and one another. As an example, the Just Like Us ambassadors have set up a WhatsApp group aimed at sharing (both LGBTQ related and more general) quarantine tips, including recipes, craft ideas and self-care advice. I think we may have also broken the world record for the number of pet photos shared in one group chat, and I am completely living for it. Ive learned so much from hearing about how other ambassadors are looking after themselves during this time.

Im looking after myself by trying new hobbies, connecting with friends and not beating myself up about everything, says Sophie. Ive found that making lists with friends of stuff you guys want to do once were out of lockdown has really given me some perspective on whats important.

Just Like Us have also launched a new social media campaign, #JLUatHome, in order to support young LGBTQ people during lockdown. The campaign has consisted of a range of content so far, including messages of support to isolated LGBTQ young people, film and book recommendations, as well as the opportunity to ask Just Like Us ambassadors questions. Through this period, we are really seeing the benefits of being part of an LGBTQ community that is still connected from afar.

If you are a LGBTQ young person, we would love you to join us by listening to our latest podcast episode, which you can listen to here. This month, ambassadors Isaac, Elly and Arber will discuss more in depth what its like being LGBTQ at home. If youre an LGBTQ teenager in the UK, we also want to welcome you into our digital ambassador team which is another way to be part of this incredible community.

Finally, if youre reading this article and want to help us to help LGBTQ young people during this difficult time, you can also make a donation to Just Like Us, but only if you are in a position to do so. You can make a gift here. Thank you!

Related: Volunteering for Just Like Us gave me confidence in my identity as a young, gay, mixed race Muslim.

Related: The invisible have voices too listen to trans youth.

Read the original here:
School is out. Many young people are not - the impact of lockdown on LGBTQ youth - Gay Times Magazine

Posted in Hormone Replacement Therapy | Comments Off on School is out. Many young people are not – the impact of lockdown on LGBTQ youth – Gay Times Magazine

Page 1,045«..1020..1,0441,0451,0461,047..1,0501,060..»